Culper Research announced that it is short Praxis Precision (PRAX) Medicines, which last month announced “positive” results from its Phase 3 trial of ulixacaltamide to treat essential tremor. The firm believe the readout appears severely compromised by an unapproved late endpoint change, optimistic imputation for a high discontinuation rate, and misuse of the cited analytical method, each of which experts believe could independently undermine FDA approval. Taken together, these issues point to significant downside risk ahead of the Q4 pre-NDA meeting as FDA scrutiny intensifies, Culper says in a note to investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Promising Future for Praxis Precision Medicines: Buy Rating Based on Robust Pipeline and Market Opportunities
- Praxis Precision initiated with a Buy at BTIG
- Optimistic Outlook for Praxis Precision Medicines: Promising Drug Pipeline and Strategic Advancements Drive Buy Rating
- Praxis Precision price target raised to $258 from $232 at H.C. Wainwright
- Promising Growth Potential for Praxis Precision Medicines: Ulixacaltamide’s Breakthrough in Essential Tremor Treatment